Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Safety and Dose Finding Study of 131I -TLX101 Plus Standard of Care in Patients With Newly Diagnosed Glioblastoma

NCT05450744 is registered in ClinicalTrials.gov with Telix Pharmaceuticals (Innovations) Pty Limited as lead sponsor.

NCT NCT05450744
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05450744 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Safety and Dose Finding Study of 131I -TLX101 Plus Standard of Care in Patients With Newly Diagnosed Glioblastoma
Lead sponsor
Telix Pharmaceuticals (Innovations) Pty Limited
Phase
Phase 1
Overall status
Active, not recruiting
Start date
April 1, 2023
Completion date
June 30, 2027
Enrollment
12 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

glioblastoma, glioblastoma multiforme, neoplastic disease